EPCAM and breast carcinoma: Based on those findings and the lack of a priori knowledge of specific surface markers when processing breast cancer liquid biopsies, we sought to use an epitope independent CTC enrichment platform to overcome the limitation in isolating claudin low and/or EpCAM negative cells.